Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Marvin Sinsakul
MedImmune LLC
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Anniston, Alabama, United States
- Research Site
Jacksonville, Florida, United States
- Research Site
Miami, Florida, United States
- Research Site
Port Orange, Florida, United States
- Research Site
Honolulu, Hawaii, United States
- Research Site
High Point, North Carolina, United States
- Research Site
Cincinnati, Ohio, United States
- Research Site
Knoxville, Tennessee, United States
- Research Site
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Sept 2018
- Primary completion
- 21 Jul 2020
- Completion
- 21 Jul 2020
- Last update posted
- 24 Aug 2020
- Registered enrollment
- 88
- Registry id
- NCT03654313
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.